Treatment with calcimimetic (cinacalcet) alters epoetin dosage requirements in dialysis patients: Preliminary report

Renal Failure

Volumn 33, Issue 7, 2011, Pages 732-735

  Fusaro, Maria ^a   D'Angelo, Angela ^a   Naso, Agostino ^a   Frigo, Anna Chiara ^b   Miozzo, Davide ^a   Gallieni, Maurizio ^c   Calò, Lorenzo A ^b  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Cinacalcet; Dialysis; Erythropoietin; Hyperparathyroidism

Indexed keywords

CINACALCET; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PARATHYROID HORMONE; PARICALCITOL;

ADULT; AGED; ANEMIA; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFECT; FEMALE; HEMODIALYSIS PATIENT; HUMAN; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SECONDARY HYPERPARATHYROIDISM;

AGED; DRUG INTERACTIONS; ERYTHROPOIETIN; FEMALE; HEMATINICS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; NAPHTHALENES; RENAL DIALYSIS; RETROSPECTIVE STUDIES;

EID: 79960809325     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2011.589937     Document Type: Review

References (29)

1. Cozzolino M.Brancaccio D.Gallieni M.et al. Pathogenesis of parathyroid hyperplasia in renal failure. J. Nephrol. 2005 18 5-8 (Pubitemid 40731458)
2. Andress D.L.Norris K.C.Coburn J.W.et al Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N. Eng. J. Med. 1989 321 274-279 (Pubitemid 19193801)
3. Block GA, Hulbert-Searon TE, Levin NW, et al. Association of serum phosphate and calcium × phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am. J. Kidney Dis. 1998 31: 607-617.
4. Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States medicare population, 1998 to 1999. J. Am Soc Nephrol. 2005; 16: 489-495. (Pubitemid 41725146)
5. Eknoyan G, Levin A, Levin NW. NKF-K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(Suppl. 3):1-201.
6. Johnson DW, Pollock CA, MacDougall IC. Erythropoiesisstimulating agent hyporesponsiveness. Nephrology. 2007;12:321-330.
7. Akmal M.Telfer N.Ansari A.N.et al. Erythrocyte survival in chronic renal failure role of secondary hyperparathyroidism J. Clin. Invest. 1985 76 1695-1698 (Pubitemid 16193595)
8. Drueke T. Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant. 2001;16(Suppl. 7): 25-28. (Pubitemid 33062119)
9. Kwack C, Balakrishnan VS. Managing erythropoietin yporesponsiveness. Semin Dial. 2006;19:146-151.
10. Messa PG, Macário F, Yaqoob M, et al. The OPTIMA study: Assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin. J Am Soc Nephrol. 2008 3: 36-45.
11. Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004 350: 1516-1525. (Pubitemid 38477776)
12. Lindberg JS, Culleton B, Wong G, et al. Cinacalcet HCL, an oral calciomimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized double-blind, multicenter study. J. Am Soc Nephrol. 2005 16: 800-807. (Pubitemid 41725117)
13. Moe SM, Chertow GM, Coburn JW, et al. Achieving NKFK/ DOQI bone metabolism and disease treatment goals with cinacalcet HCL. Kidney Int.rfpy1 2005fvn1 67: 760-771. (Pubitemid 40139871)
14. Cunningham J, Danese M, Olsonm K, et al. Effect of the calcimimetic cinacalcet HCL on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005 68: 1793-1800. (Pubitemid 43169924)
15. Brancaccio D, Cozzolino M, Gallieni M. Hyperparathyroidism and anemia in uremic subjects: A combined therapeutic approach. J Am Soc Nephrol. 2004;15:S21-S24. (Pubitemid 38018449)
16. Washio M, Iseki K, Onayoma K, et al. Elevation of serum erythropoietin after subtotal parathyroidectomy in chronic hemodialysis patients. Nephrol DialTransplant. 1992; 7: 121-124.
17. Meytes D, Bogin E, Ma A, et al. Effect of parathyroid hormone on erythropoiesis. J. Clin. Invest. 1981; 67: 1263-1269. (Pubitemid 11099340)
18. McGonigle RJ, Wallin JD, Husserl F, et al. Potential role of parathyroid hormone as an inhibitor of erythropoiesis in the anemia of renal failure. J. Lab Clin Med. 1984; 104: 1016-1026 (Pubitemid 15091145)
19. Bogin E, Massry SG, Levi J, et al. Effect of parathyroid hormone on osmotic fragility of human erythrocytes. J. Clin. Invest. 1982; 69: 1017-1025. (Pubitemid 12149180)
20. Drueke T. R-HuEpo hyporesponsiveness-Who and why. Nephrol Dial Transplant. 1995;10(Suppl. 2):62-68.
21. Rao DS, Shih MS, Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med. 1993;328:171-175. (Pubitemid 23021503)
22. Mandolfo S, Malberti F, Farina M, et al. Parathyroidectomy and response to erythropoietin therapy in anemic patients with chronic renal failure. Nephrol Dial Transplant. 1998 13: 2708-2709. (Pubitemid 28445910)
23. Chow TL, Chan TT, Ho YW, et al. Improvement of anemia after parathyroidectomy in Chinese patients with renal failure undergoing long-term dialysis. Arch Surg. 2007 142: 644-648. (Pubitemid 47080443)
24. Bamgbola OF, Kaskel FJ, Coco M. Analyses of age, gender and other risk factors of erythropoietin resistance in pediatric and adult dialysis cohorts. Pediatr Nephrol. 2009;24:571-579.
25. Al-Hilali N. Al-Humoud H. Ninan VT, et al. Does parathyroid hormone affect erythropoietin therapy in dialysis patients? Med Princ Pract. 2007 16: 63-67. (Pubitemid 44924460)
26. Viana H, Vila Lobos A, Resina C, et al. Treatment of secondary hyperparathyroidism with cinacalcet is associated with an increase in hemoglobin levels. Port J Nephrol Hypert. 2007 21: 225-229.
27. Torres P.S. Borrego Utiel F.J. Sánchez Perales MC, et al. Analysis of efficacy and factors that impact the response of secondary hyperparathyroidism to cinacalcet in hemodialysis patients. Nefrologia. 2010 30: 443-451.
28. Matias PJ, Jorge C, Ferreira C, et al. Cholecalciferol supplementation in hemodialysis patients: Effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin. J Am Soc Nephrol. 2010 5: 905-911.
29. Capuano A, Serio V, Pota A, et al. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients. J. Nephrol. 2009 22: 59-68.